Analysts See $0.47 EPS for Huron Consulting Group Inc. (HURN); Sphera Funds Management LTD Has Upped Sarepta Therapeutics (SRPT) Stake By $12.92 Million

April 17, 2018 - By Winifred Garcia

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Logo

Sphera Funds Management Ltd increased Sarepta Therapeutics Inc (SRPT) stake by 156.66% reported in 2017Q4 SEC filing. Sphera Funds Management Ltd acquired 234,997 shares as Sarepta Therapeutics Inc (SRPT)’s stock rose 36.45%. The Sphera Funds Management Ltd holds 384,997 shares with $21.42M value, up from 150,000 last quarter. Sarepta Therapeutics Inc now has $5.21 billion valuation. The stock increased 2.20% or $1.73 during the last trading session, reaching $80.19. About 381,533 shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 149.90% since April 17, 2017 and is uptrending. It has outperformed by 138.35% the S&P500.

Analysts expect Huron Consulting Group Inc. (NASDAQ:HURN) to report $0.47 EPS on May, 7.They anticipate $0.08 EPS change or 14.55% from last quarter’s $0.55 EPS. HURN’s profit would be $10.10M giving it 20.90 P/E if the $0.47 EPS is correct. After having $0.68 EPS previously, Huron Consulting Group Inc.’s analysts see -30.88% EPS growth. The stock increased 0.13% or $0.05 during the last trading session, reaching $39.3. About 21,441 shares traded. Huron Consulting Group Inc. (NASDAQ:HURN) has declined 12.86% since April 17, 2017 and is downtrending. It has underperformed by 24.41% the S&P500.

Investors sentiment decreased to 0.84 in Q4 2017. Its down 0.26, from 1.1 in 2017Q3. It fall, as 17 investors sold Huron Consulting Group Inc. shares while 39 reduced holdings. 22 funds opened positions while 25 raised stakes. 20.25 million shares or 2.32% more from 19.79 million shares in 2017Q3 were reported. The New York-based Goldman Sachs Group has invested 0% in Huron Consulting Group Inc. (NASDAQ:HURN). Van Berkom & Assoc Inc invested in 1.93 million shares. Ameritas Inv Partners owns 0% invested in Huron Consulting Group Inc. (NASDAQ:HURN) for 1,867 shares. Bridgeway Cap Incorporated has 0.02% invested in Huron Consulting Group Inc. (NASDAQ:HURN). Wellington Management Gp Llp accumulated 2.97 million shares or 0.03% of the stock. State Street holds 0% in Huron Consulting Group Inc. (NASDAQ:HURN) or 486,850 shares. Art Advisors Limited Liability Company accumulated 11,957 shares. D E Shaw & Company Inc has 143,003 shares for 0.01% of their portfolio. New York-based Bnp Paribas Arbitrage has invested 0% in Huron Consulting Group Inc. (NASDAQ:HURN). Federated Pa accumulated 0% or 49 shares. Teachers Retirement Of The State Of Kentucky invested in 20,928 shares or 0.01% of the stock. California Employees Retirement System holds 0% or 65,602 shares. Blair William Il invested in 0% or 5,065 shares. Ameriprise accumulated 37,941 shares. Deutsche State Bank Ag accumulated 86,517 shares or 0% of the stock.

Huron Consulting Group Inc., a professional services firm, provides advisory, technology, and analytic solutions in the United States and internationally. The company has market cap of $844.58 million. The firm operates through the Healthcare, Education and Life Sciences, and Business Advisory divisions. It currently has negative earnings. The Healthcare segment provides advisory services from strategy setting through implementation in the areas of organizational and resource alignment, clinical transformation, financial and operational performance, patient and caregiver engagement, and technology implementation and optimization to national and regional hospitals and integrated health systems, academic medical centers, community hospitals, and medical groups.

Among 5 analysts covering Huron Consulting Group (NASDAQ:HURN), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Huron Consulting Group had 13 analyst reports since July 30, 2015 according to SRatingsIntel. Deutsche Bank maintained Huron Consulting Group Inc. (NASDAQ:HURN) on Thursday, September 17 with “Buy” rating. As per Tuesday, January 3, the company rating was downgraded by William Blair. William Blair upgraded the shares of HURN in report on Friday, September 8 to “Outperform” rating. On Monday, September 21 the stock rating was maintained by William Blair with “Buy”. As per Tuesday, February 21, the company rating was downgraded by Barrington Research. The company was maintained on Monday, October 26 by Barrington Research. The stock of Huron Consulting Group Inc. (NASDAQ:HURN) earned “Buy” rating by SunTrust on Wednesday, October 18.

Since January 2, 2018, it had 0 insider purchases, and 11 sales for $814,920 activity. $24,488 worth of stock was sold by EDWARDS JAMES D on Tuesday, January 2. $32,666 worth of Huron Consulting Group Inc. (NASDAQ:HURN) shares were sold by MOODY JOHN S. Shares for $15,121 were sold by Zumwalt Debra on Monday, April 2. Shares for $22,577 were sold by MASSARO GEORGE. Roth James H had sold 17,500 shares worth $611,450. 190 shares were sold by LOCKHART H EUGENE, worth $7,748.

Among 27 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 21 have Buy rating, 0 Sell and 6 Hold. Therefore 78% are positive. Sarepta Therapeutics had 113 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was maintained by Piper Jaffray with “Buy” on Friday, February 9. J.P. Morgan maintained the shares of SRPT in report on Wednesday, September 6 with “Buy” rating. Robert W. Baird maintained the stock with “Buy” rating in Thursday, August 27 report. The firm earned “Buy” rating on Wednesday, February 22 by Needham. The company was maintained on Monday, October 9 by Leerink Swann. The stock has “Hold” rating by Barclays Capital on Wednesday, September 6. The company was upgraded on Wednesday, April 5 by SunTrust. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) earned “Buy” rating by William Blair on Wednesday, August 26. Piper Jaffray downgraded the shares of SRPT in report on Monday, January 18 to “Neutral” rating. Janney Capital initiated Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Wednesday, April 20 with “Neutral” rating.

Sphera Funds Management Ltd decreased Ovid Therapeutics Inc stake by 125,000 shares to 180,674 valued at $1.78M in 2017Q4. It also reduced Immunomedics Inc (NASDAQ:IMMU) stake by 220,000 shares and now owns 230,000 shares. Orbotech Ltd (NASDAQ:ORBK) was reduced too.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.